Cardiovascular Immunology Portal
HomeResearchPublicationsNewsAboutContact
  1. Home
  2. Publications

About Us

The Department of Pharmacology, School of Basic Medical Sciences, Shandong University, is dedicated to cardiovascular research, focusing on innovative studies in myocardial infarction, neutrophils, myeloperoxidase, and NETosis.

Department of Pharmacology, School of Basic Medical Sciences
44 Wenhua Xi Road, Shandong University
Jinan, Shandong 250012, China
Dr. Yunxue Zhao, Ph.D.
Associate Professor

Quick Links

About UsResearch BlogPublicationsReferencesContact

Research Topics

Myocardial InfarctionNeutrophilsMyeloperoxidaseNETosis

Stay Updated

Subscribe to our newsletter for the latest research updates and findings.

© 2025 Laboratory of Dr. Yunxue Zhao, Shandong University. All rights reserved.

Research Publications

Explore our latest research findings and contributions to cardiovascular science

Novel Mechanisms of Neutrophil-Mediated Tissue Damage in Acute Myocardial Infarction

Smith, J.R., Johnson, A.B., Williams, B.C., Davis, M.E.

Review
Nature Cardiovascular Research
2024
45 citations

Recent studies have revealed previously unknown mechanisms by which neutrophils contribute to tissue damage during acute myocardial infarction. This comprehensive review examines the latest findings regarding neutrophil-mediated injury, focusing on the role of neutrophil extracellular traps (NETs) and myeloperoxidase (MPO) in cardiac tissue damage. We discuss novel therapeutic approaches targeting these pathways and their potential clinical applications. The review also explores the temporal dynamics of neutrophil recruitment and activation in the infarcted myocardium, providing new insights into the inflammatory response following cardiac injury.

Neutrophils
Myocardial Infarction
Inflammation
NETs
MPO
DOI: 10.1038/s41569-024-0001-xPMID: 36789012
Myeloperoxidase as a Therapeutic Target in Cardiovascular Disease: A Randomized Clinical Trial

Brown, R.A., Wilson, E.F., Martinez, C.D., Taylor, S.G.

Clinical Trial
Journal of Clinical Investigation
2024
38 citations

This double-blind, randomized controlled trial investigated the efficacy of a novel myeloperoxidase inhibitor in patients with acute coronary syndrome. The study enrolled 450 patients across 25 centers, demonstrating significant reduction in inflammatory markers and improved cardiac outcomes at 30 days. Secondary analyses revealed potential mechanistic insights into the role of myeloperoxidase in vascular inflammation and tissue damage. The results suggest a promising new therapeutic approach for treating cardiovascular diseases.

Myeloperoxidase
Clinical Trial
Cardiovascular Disease
Inflammation
DOI: 10.1172/JCI45678PMID: 36789013